Clinical Trials

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

120 enrolled

Thymus Neoplasms, Neuroendocrine Tumors

NCT05988918 2026-03-06

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

66 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Phase 2 Terminated

5 enrolled 9 charts

Recurrence, Neuroendocrine Tumors

NCT04969887 2026-02-27

MOST-CIRCUIT

240 enrolled

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT04907643 2026-02-20

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

360 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Cancer Pain, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Stomach Neoplasms, Neuroendocrine Tumors, Visceral Pain

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

29 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

800 enrolled

CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT04104529 2026-02-05

BCB RIV

EndocrineGenitourinaryHead & NeckNET

350 enrolled

Prostatic Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors

NCT04459273 2026-02-05

FAPI PET RDRC

Phase 1 Active not recruiting

26 enrolled

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT04954820 2026-02-05

ReLUTH

146 enrolled

Phase NA Not yet recruiting

Neuroendocrine Tumors, Disease Progression

NCT07373015 2026-01-28

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

118 enrolled

Phase 1 Not yet recruiting

Rectal Neuroendocrine Tumors

NCT07366658 2026-01-26

NEUK203-13

9 enrolled

Neuroendocrine Tumors

NCT04505553 2026-01-21

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Phase 2 Completed

78 enrolled 14 charts

Gastro-enteropancreatic neuroendocrine tumor, Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT06122610 2026-01-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

10 enrolled

Neuroendocrine Tumors

NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

20 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

NCT04362436 2026-01-14

ArTisaN

Phase 2 Completed

24 enrolled

Neuroendocrine Tumors

NCT05987176 2026-01-14

NELMAS

Phase 2 Terminated

1 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06232564 2026-01-14

PELICAN

20 enrolled

Neuroendocrine Tumors

NCT03950609 2026-01-09

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06788886 2025-12-30

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

CNSEndocrineGenitourinaryNET

147 enrolled

Brain Neoplasms, Multiple Sclerosis, Prostatic Neoplasms, Neuroendocrine Tumors

NCT06881992 2025-12-30

Tumor HI

16 enrolled

EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT07272512 2025-12-19

ZSPAC-17

Phase 4 Recruiting

350 enrolled

Neuroendocrine Tumors

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

EndocrineGastrointestinalNETOther neoplasm

55 enrolled

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Phase 4 Recruiting

6 enrolled

Digestive System Neuroendocrine Tumor G1

NCT06889493 2025-12-17

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

36 enrolled

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06926634 2025-12-17

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

32 enrolled

Neuroendocrine Tumors

NCT04339036 2025-12-10

CapTemY90

70 enrolled

Phase NA Not yet recruiting

Neuroendocrine Tumors

NCT07274657 2025-12-10

SMILE

150 enrolled

EndocrineGastrointestinalNETOther solid neoplasm

Pancreas Adenocarcinoma (MSI-H)

NCT06735560 2025-12-08

ELEGANCE

60 enrolled

Phase NA Active not recruiting

Cirrhosis, Familial, with Pulmonary Hypertension, Carcinoma, Hepatocellular, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02743741 2025-12-03

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

195 enrolled

Neuroendocrine Tumors

NCT05263050 2025-12-03

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

EndocrineGenitourinaryNET

111 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT05178693 2025-11-24

LANTana

27 enrolled

Neuroendocrine Tumors

NCT03217097 2025-11-21

MGMT-NET

Phase NA Completed

116 enrolled

Neuroendocrine Tumors

NCT06876532 2025-11-18

LUTIBI

150 enrolled

Intestinal Neuroendocrine Tumor

NCT05255159 2025-11-17

Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors

50 enrolled

Neuroendocrine Tumors

NCT06790706 2025-10-06

IMMUNORARE5

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

154 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT07132645 2025-09-23

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

Phase EARLY_PHASE1 Recruiting

30 enrolled

Neuroendocrine Tumors

NCT06256705 2025-09-22

OPERANDI-NET

80 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT05387603 2025-09-10

START-NET

300 enrolled

Neuroendocrine Tumors

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

10 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT03457948 2025-09-03

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

32 enrolled

Neuroendocrine Tumors

NCT06878664 2025-09-02

RIALTO

166 enrolled

Neuroendocrine Tumors

NCT06908629 2025-08-26

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

EndocrineGastrointestinalNETPlasma cell

120 enrolled

Gastrointestinal Neoplasms, Multiple Myeloma, Neoplasms, Neuroendocrine Tumors

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Phase 1/2 Enrolling by invitation

52 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

30 enrolled

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Phase 1 Active not recruiting

15 enrolled